favor risk/reward new
payor paradigm upgrad ow
upgrad quest diagnost overweight equal weight rais
price target call quest favor risk-
reward profil current level recommend own share new
payor paradigm acceler opportun lab consolid new data
servic opportun learn new payor contract
notabl factor posit impact thesi think could
big deal share save prefer lab volum shift
high-cost set first lab industri primari care physician survey
show quest labcorp gain share payor network open
addit potenti chang benefit design could includ new incent
physician patient drive volum toward prefer lab would align
parti drive valu healthcar system final new contract could
acceler lab term enabl quest underwrit revenu addit
believ piec place quest meaning leverag
diagnost data asset custom highlight sever quest opportun
util data healthcar servic well clinic develop
despit recent run note share still essenti unchang last
year sinc end vs recent host meet
quest chairman ceo steve rusckowski cfo mark guinan ir shawn
bevec help confirm new view around potenti growth trajectori
compani simpli put nation lab focu deliv high valu servic
increasingli focus patient consum healthcar underappreci
amidst overarch theme industri believ quest long runway
deliv strategi acceler growth deliv oper excel
favor risk/reward profil push thesi overweight
mean labcorp top pick clearli industri theme bode
well quest also bode well labcorp see lot valu labcorp
enterpris strategi integr diagnost data healthcar servic clinic
develop trade price-to-earnings favor strategi thesi
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight
rais usd
return equiti ttm
link barclay live interact chart
overweight believ quest long
runway deliv strategi acceler growth
deliv oper excel point new
payor relationship help drive lab test share
toward nation lab time addit
believ quest meaning leverag
diagnost data asset custom
upsid case assum quest aggreg
increment test share drive upsid
case ep earn begin
acceler believ multipl room
expans well given long runway
downsid case assum softer util
well increment wage pressur busi
cost repres downsid
case ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
action upgrad overweight pt rais forecast
number catalyst year
also headlin around pama monitor
later labcorp top pick
upgrad overweight equal weight rais price
target call quest favor risk-reward
profil current level recommend own share new payor paradigm
acceler opportun lab consolid new data servic opportun
learn new payor contract notabl factor
posit impact thesi think could big deal share
save prefer lab volum shift high-cost set first lab
industri primari care physician survey show quest labcorp
gain share payor network open addit potenti chang benefit design
could includ new incent physician patient drive volum toward
prefer lab would align parti drive valu healthcar system final
new contract could acceler lab term enabl quest underwrit
revenu addit believ piec place quest meaning
leverag diagnost data asset custom highlight sever quest
opportun util data healthcar servic well clinic develop
despit recent run note share still essenti unchang last year
sinc end vs recent host meet
quest chairman ceo steve rusckowski cfo mark guinan ir shawn bevec
help confirm new view around potenti growth trajectori compani
simpli put nation lab focu deliv high valu servic increasingli
focus patient consum healthcar
underappreci amidst
overarch theme industri believ quest long runway deliv
strategi acceler growth deliv oper excel favor
risk/reward profil push thesi overweight
action upgrad overweight pt
rais forecast
upgrad overweight equal weight rais price
target view quest favor risk/reward
profil valuat methodolog take weight averag potenti scenario
partial account lab consolid opportun new payor paradigm
believ investor good visibl result least achiev
base case scenario forecast ep repres growth y/i
squar middl quest long-term guidanc mid-to-high singl digit
earn growth increas prior forecast quest
sever compel opportun augment growth new aetna
payor renew net posit quest base case forecast modest
contribut consolid barrier entri break nation lab
addit encourag quest effort leverag diagnost data asset
drive valu health system custom util trend remain stabl driven
grow popul age demograph well push toward
person medicin importantli pama embed forecast
believ worth own share given potenti leverag upsid
lab consolid driven new payor paradigm upsid case
assum quest aggreg increment test share drive upsid
ep forecast benchmark keep mind quest labcorp
collect aggreg share earn acceler believ
multipl room expans well given long runway potenti
consolid likelihood year number also trend higher growth
frankli dont believ signific downsid point worst case
scenario pama number model cut
addit recent renew nation payor contract improv visibl
long-term relationship chang contract paradigm way favor
nation lab valu proposit downsid case assum softer
util well increment wage pressur busi cost see
limit probabl downsid point given new payor contract improv
near-term rate visibl lead increment volum opportun
oper effici quest signific runway continu pull cost
busi autom procur lab footprint consolid
price repres blend blend ep scenario analysi
yield multipl ep forecast prior price
target repres prior ep forecast
price base weight averag scenario analysi
rais forecast revenu ep
epsmultipleoutcomerel pricenotesbas lab share revenue upsid epsdownsid volum wage pressur adj adj researchconsensusbarc vs streetbarclay research barclay quest diagnost
pleas see report
day preview see proof
point global life
pleas see report
deliv proof point
global life scienc
number catalyst year
late summer earli fall could provid addit detail relat
potenti chang lab benefit structur highlight econom incent
drive share toward prefer lab partner includ quest labcorp
capit deploy pace acquisit slower start
quest dialogu remain activ view time function rapid
pace deal-mak end quest guidanc call growth
acquisit believ addit deal would drive upsid target
share shift lab share could start shift advanc new payor contract
start nation lab salesforc deliv messag account
would repres upsid forecast bullish signal come
analyst day novemb possibl quest provid updat
compani data servic strategi highlight progress made leverag
data asset custom time year quest could announc dividend
rais time also expect quest affirm long-term outlook think
could meaning upsid industri consolid like earli call
inflect novemb contract start
earli januari new payor contract implement commentari
healthcar industri confer could provid detail earli experi lab
nov/dec tradit host annual investor day new lab
strateg partnership could one area highlight investor commun
march possibl barclay global healthcar confer
miami beach mark calendar quest could highlight continu experi
new payor contract aetna
also headlin around pama monitor
summer/fal outcom acla court case hh relat pama
expect deliv frankli hope pama stay place provid
price transpar highlight valu proposit nation lab
manag exposur success cut addit
pama alreadi drive consolid given greater exposur peer final
reason believ pama could lead disciplin commerci price view
litig nois relev short-term invest thesi
later labcorp top pick
natur question expect field mean labcorp top
pick clearli industri theme bode well quest also bode well labcorp
see lot valu labcorp enterpris strategi labcorp leader integr
diagnost data healthcar servic clinic develop labcorp analyst day
demo around new xceller tool impress one reason
excit futur may hold quest well addit labcorp led
manag team hold high regard diagnost execut robust
growth cro busi gain momentum mid-to-high singl digit organ
growth forecast industri partnership drive long-term growth trade
price-to-earnings vs quest favor strategi thesi
believ sever recent strateg chang lab industri creat opportun
valuat expans nation lab sinc lab trade prolong
discount market first market broadli dislik nation exclus
relationship labcorp quest sign aetna respect
second nation exclus payor contract enabl region lab
better compet nation lab earn share third reset industri price led
seri annual unit price headwind fourth hospit consolid physician
practic led insourc test fifth uncertainti around medicar reimburs
chang abil manag cut persist sourc nois simpli put
nation lab new payor paradigm markedli improv visibl sever factor
expect nation lab valu proposit differenti us healthcar
industri increasingli focus pay-for-valu
lab valuat improv still trade discount histor consolid period price ntm earn
lab trade discount despit improv fundament strateg posit consolid opportun
relationship major shift
opinion payor
put place new tool
encourag physician steer
network high qualiti
laboratori deliv good
think big deal
share save
prefer lab volum
shift high-cost set
first lab
continu think share
dynam labcorp quest
vs rest industri
far materi relev
share dynam
two nation lab
believ opportun ahead quest compani new contract
cover steve valiquett help break barrier
nation lab consolid share test improv patient experi
payor remind quest labcorp announc new contract
may view game-chang industri previous
quest labcorp exclus relationship aetna cover
respect open januari new unitedhealth
relationship major shift opinion payor put place new tool
encourag physician steer patient toward prefer network high qualiti
laboratori deliv good valu could provid detail potenti new
benefit design sometim later summer/earli fall order market plan
year though time ultim hand dont want rule time could
get delay well quest provid framework benefit design
could look like includ prefer network laboratori base valu
specimen patient wait time etc capabl around price transpar tool
real-tim auto adjud given differenti invest quest
labcorp consum tool real-tim auto adjud vs region
peer two nation lab would obviou beneficiari prefer network
implement
think could big deal share save prefer lab
volum shift high-cost set first lab industri volum
shift high-cost provid toward prefer network plan
develop pool save share provid instead
commodit lab lab result qualiti metric differenti
particip price tool incentiv effici deliveri care encourag
util prefer network also consid put place
econom incent patient physician adher network would
also first histori lab industri would includ waiv out-of-pocket
cost patient co-pay deduct encourag adopt given
rapid growth high-deduct health plan past decad believ could
drive strong incent patient better direct shift volum
discuss next continu think share dynam labcorp quest vs
rest industri far materi relev share dynam
two nation lab said obvious share shift
quest labcorp aetna contract open
believ net yield modest benefit quest modest
headwind labcorp simpl math larger aetna would
suggest quest net beneficiari vice versa labcorp said fact
labcorp earn price increas critic element
deal calculu also cement truli paradigm shift industri
base case analysi assum around ebitda tailwind quest
around ebitda headwind labcorp
rate quest note think got fair price good
market valu move out-of-network provid in-
network statu actual creat price headwind quest also great job
exemplifi lab industri issu first place analysi peg
discount visibl low statist less relev full
analysi given small current size revenu payor importantli
note labcorp messag compani receiv price increas
larger size revenu believ modest peg
volum quest expect substanti gain
compani quest note dynam differ time around network
open lab analysi assum base case volum
shift labcorp quest though imposs quantifi point
would increas quest share revenu estim
pro-forma
similarli aetna quest expect cede volum back labcorp back in-
network assum percentag volum shift equival volum shift
though also imposs quantifi point also assum
similar price dynam new contract would increas
labcorp share revenu aetna estim pro-forma
base case estim potenti price/mix chang aetna contract mm
note estim base histor disclosur labcorp quest file total compani ebitda quest prior forecast report
payor enu shift mmlabcorpquesttot labstot totallab chang lab chang lab shift mmlabcorpquesttot labstot totaltot lab chang lab lab compani impact mmlabcorpquesttot ebitda compani ebitda barclay quest diagnost
clearli much bigger opportun quest labcorp test consolid
lab across payor repres industri look back
past decad obviou nobodi origin nation exclus
contract nation lab nation payor patient quest note
nation payor recogn need work nation lab better drive
valu system old contract allow region lab better penetr physician
offic could arbitrag benefit fact nation lab out-
of-network one nation payor drove higher price nation payor
overal higher out-of-pocket cost patient quest believ old payor
paradigm drove complex physician would field question
patient around unexpect lab cost back in-network remov unnecessari
barrier compet nation lab quest note earn
new volum earn volum across payer quest
look flip physician offic quest earn full book busi
compani start low-hang fruit quest domin physician offic
except volum alon quest ear-mark invest
make sure enough phlebotomist courier handl increas demand well
commit salesforc incent drive home addit volum quest
salesforc individu span geograph territori across countri
quest think share could move quickli commerci execut
get messag obviou headwind account prefer
peer quest equal need defend turf number get larg quickli
current valuat believ investor free call option potenti
consolid upsid outsid hospit lab opportun size around
billion nation lab repres share everi market share
assum meaning price discount quest fee schedul yield million
addit revenu quest growth quest estim increment margin
would impli earn growth almost pull-through believ
best outcom investor lab industri consolid organ
payor drive share nation lab hand without need cash outlay
outsid hospit opportun
increment ep increment share gain
consolid test major theme coverag past year
believ see earli signal result acceler quest
labcorp quest post lab growth includ organ
acquir growth quest best growth sinc labcorp post
increment revenu growthincrement share pieincrement quest rev mminc marginpric discount quest fee schedul barclay quest diagnost
total lab growth includ organ acquir growth
labcorp best growth sinc sinc averag revenu growth
lab highlight recent acceler growth consolid
total revenu growth lab busi
organ revenu growth lab busi
last week perform survey primari care physician get sens
new payor relationship would impact order pattern lab volum
sampl size small would difficult get materi result given number
physician lab serv us said goal gaug
physician may chang order pattern new payor contract
implement individu result highlight real consolid
opportun labcorp quest network open collect physician
cite order routin diagnost test patient year averag
screen physician order routin test patient per year
order get meaning size physician offic addit screen
physician affili health system want receiv respons
physician affili hospit send volum said hospit given
chang econom incent payor patient physician certainli
possibl could opportun physician affili hospit well
look median respons network access import factor cite
survey behind test qualiti categori survey survey scale
import import pleas assign valu follow criteria
around import choos lab partner seven attribut network
statu patient pocket expens phlebotomist access qualiti test salesperson
relationship total cost test turnaround time median respons network
access finish second behind test qualiti look
anoth way ten respond answer network access
import tie second behind test qualiti believ respons
support view network access import consider physician
order test aetna contract open believ
break barrier entri nation lab
median respons import
import show valu network access
import respons criteria also
demonstr import
result also support thesi real overal opportun lab share
gain rest test pie directli quest labcorp ask
physician two question thereaft first last year estim mix
routin lab test volum across follow lab provid second jan quest
labcorp return in-network statu aetna respect
in-network barrier patient expect impact
mix routin lab test across follow lab provid obvious becom
new realiti januari lab expect gain share quest
expand labcorp expand
volum mix lab provid last year
expect volum mix lab provid unh/aet
contract open
believ look specif custom respons relev
nation lab wide expect gain share physician consolid provid
quest labcorp expect gain share physician respect
wide margin hospit lab independ lab
respect dig custom expect labcorp
quest gain share vs hospit independ lab peer addit hospit
independ lab led way share loss custom level quest
labcorp expect lose share custom respect
meaning less hospit lab independ lab respect
nation lab expect gain share
account network open
convers competit expect lose share
account network open
region northeast area quest labcorp univers
perform well surpris given lab strength region
custom expect nation lab gain share respons region
custom cite low cost quest labcorp custom cite
number high qualiti attribut nation lab instanc hospit lab
expect lose share quest also perform notabl well west coast lab
expect gain share custom respons region
respons detriment hospit lab independ lab
data also highlight mix shift labcorp
quest clearli bigger opportun hospital/region lab
instanc quest labcorp trade share favor quest favor labcorp
context observ believ nation lab gain share
state regionvolumeslhdgxhospit laboth ind lablhdgxhospit laboth ind lablhdgxhospit laboth ind labwhi lab send test non-dgx/lh use dgx/lh interfac quick result reliabl accuratenew other due networknew specif cost mattersnew patient self pay patient get better price labcorp total network save patientnew qualitynorth reliablenorth labnorth hospit lab placenorth accessnorth requir use labcorp aetna quest good mid-atlant total organ quest recent chang labcorp happi best rate next day result result directli fax labcorp high qualiti lab larg varieti labcorpwest mainstream tests/therapi patient conveniencemidwest total use hous type test insur local labcorp requestsoutheast clinic hous lab multispec requestsouth total use quest mostli due interfac order result local pacif diagnost cost quick turn around lab contract volum best industri integr well union worker pclwest coast total volum lab provid last year mix volum lab provid network open chang share barclay quest diagnost
diagnost data critic
system transit pay-
pleas see report
show increas role data
pleas see report
end market read
believ piec place quest meaning leverag
diagnost data asset custom point believ role valu
healthcar data system undeni us healthcar system increasingli
transit away fee-for-servic toward pay-for-valu think progress
transit best exemplifi recent consolid amongst payor provid pbm
retail healthcar servic industri diagnost data critic system
transit pay-for-valu unitedhealthcar presid schumach sum
best announc around new strateg partnership lab data
quickli becom person roadmap identifi path next best action
individu patient data strategi core tenet labcorp iqvia
overweight thesi encourag quest made signific progress
front well era person medicin diagnost data uniqu abil
inform better healthcar outcom diagnost data repres total
healthcar spend inform decis physician make
overal quest diagnost servic platform repres around billion
compani revenu around provid leverag base growth move
forward busi includ number busi includ employ insur
well data analyt extend care servic profession lab servic
busi grow mid-to-high singl digit see lot
opportun ahead highlight sever quest opportun util data
healthcar servic deliveri well clinic develop
quest highlight sever way util patient
data better inform patient care bend cost curv simpli put payor
interest target high-risk patient earlier prevent costli
oftentim prevent diseas real opportun non-acut care spend
repres around us healthcar cost quest data patient
reach psc retail relationship disrupt insur incentiv
drive better health outcom member order improv hedi
score medicar star rate exampl highlight quest
quest focus popul health look leverag recent
acquisit medxm medxm perform basic healthcar servic quest
data help identifi costli patient help seek care locat
much access help manag patient popul close
gap care drive intervent patient becom less expens resourc
 quest note success payor target pre-diabet patient
high statu payor work proactiv work
address issu given quest longitudin record patient data payor
monitor statu work bring target rang
diet/exercis medicin quest provid measur result drive
overal econom valu importantli risk healthcar outcom
 quest joint ventur work drive basic healthcar
servic retail set potenti servic includ hear test blood pressur
monitor diabet care initi pilot includ store futur
opportun expans beyond
clinic develop quest opportun time leverag
diagnost dataset pharma sponsor major challeng clinic trial
enrol includ select high-qual site find high-qual patient
match criteria research patient adher trial
start quest labcorp add valu clinic trial process use
diagnost data sever reason nation lab rich diagnost data given
patient access abil retain test result year addit
nation lab diagnost data identifi patient level lab
consum tool could enabl contact patient directli trial enrol
elig final nationwid footprint patient servic center new retail
locat potenti leverag clinic trial process broaden access
patient enrol pharma sponsor abil power number
patient clinic trial lower higher qualiti patient help reduc cost speed
path market also help improv qualiti patient enrol one
uniqu aspect quest approach compani pharma
sponsor cro agnost wherea iqvia labcorp captiv
cro quest work directli pharma sponsor market data offer
note substanti interest initi feedback custom
broadli healthcar data get access robust cohes allow
pharma compani util dataset uniqu way describ
detail see four primari sourc data prescript drug data electron health
record ehr data health vendor diagnost test data site
effici data intern cro databas central laboratori function believ
integr data help sponsor optim drug develop reduc cost better
target patient special indic improv sponsor invest return
coupl accommod fda
hospit basic ehr system instal
offic nation coordin health barclay research
growth sequenc data accumul billion base
advantag quest labcorp compani diagnost data
identifi patient level could lead effici site select
patient recruit tool time select patient recruit
biggest pressur point sponsor patient recruit one difficult
activ clinic trial thu histor pose number issu biopharma
sponsor act outsourc catalyst cro industri drug
therefor trial becom special find elig patient clinic trial
becom inher difficult leverag data sourc biopharma sponsor
totalal hospit basic ehr barclay quest diagnost
cro produc heat map elig patient locat speed
recruit investig site select addit target high-perform
investig run trial reduc number site need improv qualiti
trial well patient adher rate data collect etc time expect
quest labcorp util diagnost data help better inform sponsor
around patient recruit potenti use consum tool patient servic
center recruit patient adher
data sourceproviderscro usersstrategyr world exampleprescript datavari healthcar provid synhus prescript data locat patientsscript data inform cro around patient current therapi certain condit data inform focu patient recruit effort ehr datahealth supplier parexel iclrus ehr data locat patientshealth record contain comprehens medic inform use creat heat map patient recruit real-world evid studi diagnost testinglh fmilhus identifi biomark statu lab test result recruit patientstest record show investig patient meet biomark criteria clinic trial compani faster target site larg cluster desir patient labcorp patient consent strategi compani contact patient directli central lab testinglh iclrlh iclrus biomark statu inbound kit identifi top tier investigatorsth central lab tell inbound kit investig larg cluster patient desir biomark statu compani turn use knowledg recruit futur trial faster barclay quest diagnost
believ near-term setup volum growth attract given favor
pace comp quest number driver plan pursu growth
includ organ growth payor network chang industri consolid underli
util trend mostli unchang quest posit lab industri
continu benefit grow popul age demograph quest note
employ labor growth remain healthi drive procedur growth
industri unemploy time low churn employ creat test
opportun employ screen advanc diagnost continu bright spot
grow mid-singl digit hope acceler high-singl
digit addit quest beneficiari test prescript drug
monitor major payor waiv prior author requir
nation lab order incentiv share toward consum test continu
trend posit quest highlight relationship ancestri com serv
lab test provid along also believ retail strategi bear
fruit quest almost retail locat point two nation retail
psc quest believ eventu psc candid retail
set time mostli includ older site smaller facil could
better locat convers vitamin women health test categori
neg women health mirror commentari
attribut pressur januari februari sever flu season weather
improv march quest note exposur potenti uspstf guidelin
chang pap test modest look ahead comp favor next
two quarter especi modest tailwind time
y/i sequenti
also
favor move signific tailwind given impact hurrican
harvey irma maria oper prior year quarter believ volum growth
could acceler higher next two quarter ahead
opportun new payor contract
lack sever weather flu season
reimburs encourag pama could potenti lead
stabil commerci payor rate lack headwind could major
tailwind off-set pama time quest note commerci payor
interact understand pama price transpar highlight substanti valu
proposit nation lab provid health system medicar rate
reset lower given commerci price serv new benchmark
medicar reimburs think possibl could lead ration
commerci contract lab point labcorp price increas
renew highlight one paradigm shift industri quest cfo
mark guinan note brought new price disciplin contract sinc join
compani year ago think serv quest well long run point
quest continu expect pama rate headwind
remain enact plan mirror forecast expect beyond
pama commerci unit price headwind per quarter recent
pleas see report
revenu driver diagnost quest model
assumptionstot growth equival trial total test y/i lab organ total requisit y/i y/i organ net new weather calendar underli ppa per y/i y/i organ rev medicar pama overal y/i organ growth barclay quest diagnost
contract unitedhealth
 win-win
parti
believ one under-appreci aspect new contract
also chang way quest abl pursu futur
win-win parti quest buy hospit outreach busi compani
histor underwrit transact base quest fee schedul
past pose two critic problem revenu would immedi need reset lower
onto quest fee schedul quest would assum busi
would disappear follow transact close would make
acquisit imposs complet despit best interest payor
save money get higher qualiti result quest own lab new
contract two import fix quest underwrit
busi longer disappear agre
allow rate step time vs immedi reset quest fee
schedul appear win-win quest
capit deploy quest expect continu return major capit
back sharehold dividend repurchas program
collect repres capit deploy compani dividend
price around yield increas last year beyond
tuck-in compani prefer quest continu expect contribut
growth year assum per year long-term
guidanc quest note dialogu remain activ health system
fewer announc start time relat anyth els given
activ close expect capit expenditur remain elev
level near-term quest reinvest tax reform save build new
facil new jersey serv east region expect open quest
manag ultim compens growth expans view
well align sharehold
histor mix capit deploy
labcorp quest deploy billion collect toward largest
amount sinc labcorp kick deal activ acquisit mt sinai
outreach oper follow sizabl paml acquisit ad million
refer lab test busi affili provid system cathol
debt ttm barclay quest diagnost
initi quest activ year acquisit announc total eight
deal quest close shield medic lab acquisit amongst other deploy
million quarter deal includ million acquisition/partnership
peacehealth
million acquisit
medfusion/clearpoint texa final sonic gotten action two jv
nyu nyc western connecticut network deal activ easili
eclips million lab industri revenu aggreg us
industri revenu look tabl clear pace
partnership acquisit pick
 clinic laboratori acquisit partnership
believ uptick laboratori deal activ partial attribut pama
uncertainti major driver thesi industri updat
reimburs laboratori test went effect januari clearli
mind industri particip hospit laboratori view non-cor part
health system ideal area hospit gener save strike deal
labcorp quest allow hospit focu core busi continu
provid patient access qualiti laboratori servic mani hospit system
alreadi financi pressur pama repres increment risk drive
manag team chang decision-mak
yeardealslabtarget/partnerdatetyp sinai region laboratori associ outreach clinic outreach medic laboratori jvquestcap cod care outreach acquisitionquestm fusion associ medic laboratori laboratori outreach acquisit servicessonicwestern connecticut network venturequestmontefior serviceslabcorpmount acquisitionlabcorpclearpath lab lab acquisitionquesthca serviceslabcorphenri mayo newel acquisitionquestclin laboratori partner hartford outreach acquisit barclay quest diagnost
quot pama impact consolid
speakerquotequest ceo steve rusckowski part discuss hospit system around lab strategi see pressur rate broadli feel pressur commerci insur relationship also look forward realiz clinic ip schedul refresh talk past exposur medicar roughli revenu much meaning percentag laboratori revenu engag convers one aspect consider around outreach go pressur commerci side well medicar aspect know relat strategi want put capit increasingli complic area case decid second realiz scale signific move away fee-for-servic model much value-bas reimburs model longer go activ go make sure best cost per servic unit cost structur far superior cost structur mani case engag around case bought outreach busi see reimburs chang believ move team someon like quest effici model deliv necessari diagnost servic part overal strategi integr deliveri system part look pressur rate comprehens well labcorp ceo dave king think part convers hospit lab anticip potenti impact pama think part convers uncertainti around gener regulatori reform much bundl payment demonstr thing go continu form take talk managed-car partner push toward probabl character value-bas payment value-bas payment includ bundl payment includ pay outcom includ pay adher metric think lot hospit health system focus core compet deliv value-bas care partner gain compet elsewher think diagnost laboratori servic drug develop obvious compet capabl industri lead think combin thing think environ obvious chang benefit lot long-term plan partnership take shape valu long term peacehealth lab ceo ron whitehead ron whitehead presid peacehealth lab deni health system financi strap tell dark report organ strong stabl whitehead indic laboratori sold new feder legisl known pama would reduc reimburs percent start juli http //www thelundreport org/content/paml-announces-sale-labcorp cape cod healthcar cchc ceo michael lauf cost provid servic higher competitor marketplac insur govern payer demand lower cost made clear expect continu reimburs us full cost test long term sourc sweat bullet sourc http //www captodayonlin com/ownership-remix-hospitals-national-labs-jockey-position/paul camara princip appli management barclay quest diagnost
quest continu signific runway improv oper excel
includ focu collect procur autom lab consolid
launch invigor program on-going program focus increas
product improv margin compani target cost save per year
import off-set wage inflat unit price headwind
describ earlier pick-up consolid would help drive healthi increment
margin busi model assum margin expand per year
light pama quest near-term forecast assum leverag
time well revenu growth mid-to-high singl digit earn growth
collect quest leverag auto-adjud capabl
payor improv up-front collect patient quest note payor
notabl realli valu auto-adjud capabl sinc provid
price transpar patient avoid unexpect patient bill draw
complaint member roughli quest volum compani
actual perform draw depend patient insur compani
determin quickli much person oblig pay good
confid request payment test order biggest issu bad debt
volum quest perform blood draw help
quest team optum help improv effici quest note
compani bad debt rate lowest psc higher in-offic phlebotomist
highest physician offic draw
procur quest goal year drive improv cost paid
supplier quest ad similar relationship payor compani
get better around partner work togeth supplier reduc
cost quest note continu good innov amongst ivd
manufactur cite aliquot major advantag save cost
implement pama quest look pass headwind
manufactur mostli routin test cut meaning quest
note compani relationship good quest valu market
team togeth vie compani good partner
look quest footprint believ compani continu long
runway drive consolid network effici high level labcorp
footprint appear significantli consolid quest today
medicar provid util data take-away quest clearli
signific runway consolid region lab footprint time background
publish medicar data annual nation provid identifi npi level
provid uniqu perspect lab trend individu lab data sole
medicar part bill code inpatient/outpati test
data impress detail downsid take month
follow end year actual publish data also scrub
histor data attempt captur lab histor acquisit well
pleas reach us copi data warn file mb
punchlin labcorp top npi repres medicar revenu
vs quest labcorp burlington nc lab largest facil repres
total medicar revenu believ compani raritan site actual
largest overal lab medicar revenu repres total
contrast quest lab surpass total medicar revenu
tampa fl total
pleas see report
lab
futur takeaway focu
oper effici
agre quest view compani signific opportun consolid
region footprint believ quest success consolid northeast region
serv good benchmark futur opportun remain region
east coast target next new lab built new jersey northeast region
quest cover total countri stretch main pennsylvania
ohio though exclud nyc philadelphia teterboro compani run
vast major test two lab marlborough pittsburgh pa
process consolid region quest close laboratori includ
compani previou oper cambridg out-grew facil
crowd area facil raleigh ct acquir athena diagnost facil
worcest boutiqu lab peabodi small cytolog lab rhode
island compani investor day quest tout northeast region
exhibit double-digit revenu growth margin improv doubl rate
quest note payback invest incred quick given improv
product equip effici logist public sourc cite total
invest million facil one advantag marlborough site
floor lab set-up like one big footbal field wherea compani
laboratori small begin addit area ad
time econom import driver decis consolid
qualiti improv also seen dramat improv exampl quest
highlight abil manag patient sampl compani loss sampl alreadi
six sigma level marlborough laboratori doesnt happen quest also note
less human directli handl sampl better qualiti autom
platform ensur right sampl place right tube right test
perform addit decis consolid test allow quest expand
menu test offer site abil improv tat given quest doesnt
submit test result final test perform lower tat allow better patient
qualiti faster re-ord test physician want look addit metric
submit sampl
note appear quest region could benefit level
consolid quest next target along mid-atlant build new
million facil new jersey expect potenti open mani
compani region lab area consolid new facil includ
compani teterboro site compani region compani believ
implement exact layout
medicar revenu quest region
hospit system import sourc revenu inpati volum trend
recent pressur think import monitor hospit
volum trend shown also believ metric becom less relev
time consum drive site care chang toward altern set retail urgent
care etc shift care inpati outpatient/altern set ultim
wash nation lab potenti net posit given lab
valu proposit fact hospit also lab competitor
note urban hospit includ tenet acut care rural includ lifepoint commun health
pleas see report
employ growth import driver healthcar util diagnost
volum mind unemploy current histor low
provid better method track employ trend lab respect geograph
footprint provid in-depth review bureau labor statist bl
metropolitan area employ unemploy summari month
inform releas monthli bl provid updat employ
situat counti unit state use data method track
employ condit underli market labcorp quest patient
servic center psc psc import sourc revenu gener
two nation laboratori repres approxim revenu employ
growth one driver lab util impact health insur rate
employ screen believ report provid use method track
underli econom perform compani region footprint base
model counti analysi look county-level psc locat match
employ data specif county-specif model creat
weight psc concentr bl employ data counti lab
oper pleas let us know would like addit data
overal unemploy lab coverag remain histor low april
unemploy improv y/i par nation averag
trend labcorp quest market remark consist
extend period time look back
histor unemploy rate model counti vs nation averag
employ trend lab par nation averag y/i
versu nation labcorp modestli outperform quest excess
employ growth note averag employ growth lab
flat sequenti addit stack growth averag lab
employ trend averag lab model counti vs nation averag
labor forc trend lab nation averag y/i labcorp
modestli outperform quest labor forc market versu
quest note averag labor forc growth lab decreas m/m
addit stack growth lab higher nation level
labor forc trend averag lab model counti vs nation averag
similarli approxim half cost requir oper quest labcorp lab
busi labor relat monitor wage expens import good news
major quest workforc alreadi earn wage nation minimum
wage laboratori technician skill requir variou certif
compani phlebotomist near term quest proactiv invest per
employe one-tim bonu respons signific benefit tax reform
time quest continu drive autom facil help
keep underli cost check
season adjust
adjust
million except per share dataestestestestestestestincom increas debt debt debt gross lab increas equival organ increas net margin net sg net comp sg net increas intang oper ebitda margin net oper profit ebit margin net interest expens debt share earn joint expens pre-tax pre-tax provis incom tax net net average share average share ep ep increas item net net increas ens net incom growth net ep growth ebit ebit margin net ebit margin gross barclay quest diagnost
statement flow
million except per share dataestestestestestesteststat doubt incom tax share compens benefit associ stock restructur payabl accru settlement tax asset chang work paid sale sale royalti y/i increas invest stock tax benefit per growth non-control financ chang cash cash cash includ asset held equival begin equival end adj net barclay quest diagnost
estestestestestestest million except per share incom expens incom equitycurr liabilitiesaccount payabl accru term debt ltd current term sharehold liabilit barclay quest diagnost
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
